MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.jmedchem.6c01714

Медицинская библиотека · Journal of medicinal chemistry · 2026

Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.

Wang Wenchao, Li Dan, Liu Jin, Li Lei, Zhang Qi, Zhang Facai, Liu Yang, Zhang Yifan, Meng Shuai, Shi Xuyang, Wang Hong, Li Qingyong, Zhang Dahong, Mao Zujie

СтатьяПеревод в очереди

Аннотация

Bladder cancer is a malignant tumor with a high incidence and mortality worldwide. Clinically, DNA-damaging agents such as cisplatin, irinotecan, and gemcitabine are commonly used, but their efficacy is often limited by acquired resistance. A key resistance mechanism involves the upregulation of PARP1 in response to drug-induced DNA single-strand breaks (SSBs), which diminishes the therapeutic effect. To overcome this obstacle, we designed and synthesized a series of united TOP1/PARP1 inhibitors that simultaneously induce SSBs via TOP1 inhibition and block their repair via PARP1 inhibition, converting repairable SSBs to lethal double-strand breaks (DSBs). Among these, compound D5 exhibited excellent dual-target inhibitory activity and effectively overcame cisplatin resistance, demonstrating potent antitumor efficacy in vitro and in vivo (TGI = 65.7%). Collectively, D5 represents a promising TOP1/PARP1 inhibitor for overcoming resistance to conventional DNA-damaging chemotherapies.

Для цитирования: Wang Wenchao, Li Dan, Liu Jin, Li Lei, Zhang Qi, Zhang Facai, Liu Yang, Zhang Yifan, Meng Shuai, Shi Xuyang, Wang Hong, Li Qingyong, Zhang Dahong, Mao Zujie. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.. Journal of medicinal chemistry. 2026. DOI: 10.1021/acs.jmedchem.6c01714.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.